ArticleRegenerative therapy2025
Revolutionizing nerve regeneration: A novel approach using polylactic acid/chitosan conduit with nerve-like cells and
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This research aims to use neural-like cells (NLCs) derived from endometrial mesenchymal stem cells (EnMSCs) on a polylactic acid/chitosan scaffold (PLA/CS) along with the use of Method: EnMSCs were isolated, characterized, and differentiated in a study. The expression of specific genes in the differentiated cells was confirmed using RT-PCR and immunocytochemistry. PLA nanofiber and chitosan hydrogel scaffolds were created for neural tissue engineering. Memocopa was administered orally alongside scaffold and cell transplantation. The study involved 25 adult male Wistar rats with a 3 mm sciatic nerve gap, divided into five groups based on treatment. Animals were monitored for 8 weeks, during which SFI was measured. Tissue samples were then prepared for histological examination, including various staining techniques. Results: The combination of scaffold, cells, and Memocopa showed significant improvements in sciatic nerve function, as indicated by the SFI results in the eighth week: conduit group -33.87, conduit/cells group -25.92, conduit/cells/Memocopa group -22.86, Memocopa group -30.93, and control group -38.87. Histological findings revealed improvements in various aspects, including percentages of new nerve formation across the different treatment groups: conduit group 4.62 %, conduit/cells group 16.45 %, conduit/cells/Memocopa group 21.32 %, Memocopa group 7.07 %, and control group 0.22 %. Conclusions: The results of this study showed that efficient differentiation of EnMSCs into NLCs is possible, and with the help of PLA/CS scaffold and simultaneous use of Memocopa, it is possible to repair and improve sciatic nerve injury in a rat animal model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.